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Second malignancies in patients 
with early stage (I, IIa, IIb) seminoma treated 
with post-orchidectomy radiotherapy
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Zofia Ko∏osza3, Rafa∏ Tarnawski1
P u r p o s e.  The evaluation of the risk of second non-germ cell malignancies after radiotherapy for early stage seminoma (I,
IIa, IIb – according to Royal Marsden Hospital classification).
M a t e r i a l s  a n d  m e t h o d s.  A retrospective analysis of 164 patients with stage I, IIa, IIb seminoma who were treated
between 1974 and 1990 with post-orchidectomy irradiation, was performed. 48% of patients had been treated with
infradiaphragmatic radiotherapy only (IDRT), while in the remaining 52% prophylactic mediastinal and left supraclavicular
irradiation (supradiaphragmatic radiotherapy SDRT) was performed additionally. Median follow-up was 12 years. The risk
(O/E) of a second non-germ cell malignancies was estimated by the ratio of the observed number of second malignancies in
the analysed group to the expected number of malignancies in the age-adjusted male population.
Re s u l t s.  Overall 5-year and 10-year survival was 92% and 86%, respectively. Twelve patients (7%) developed 13 subsequent
non-germ cell malignancies, with a mean interval of 10 years after radiotherapy. The relative risk of second malignancies was
3.55 (95%CI – 1.89-6.07) and was significantly increased. The risk of lung cancer (O/E – 5.55; 95%CI – 2.03-12.04), and
rectal cancer (O/E – 11.76; 95%CI – 1.39-41,62) was significantly increased, as compared to the age-adjusted male
population.
C o n c l u s i o n s.  The risk of second malignancies is significantly increased in patients with early stage seminoma treated with
post-orchidectomy radiotherapy.
Wtórne nowotwory u chorych we wczesnym stopniu zaawansowania nasieniaka jàdra
(I, IIa, IIb), u których zastosowano pooperacyjnà radioterapi´
C e l.  Ocena ryzyka wtórnych niezarodkowych nowotworów u chorych na nasieniaka jàdra we wczesnym stopniu
zaawansowania (I, IIa, i IIb – wg klasyfikacji Royal Marsden Hospital), u których przeprowadzono uzupe∏niajàcà radioterapi´.
M a t e r i a ∏  i m e t o d y.  Retrospektywnà analizà obj´to grup´ kolejnych 164 chorych na nasieniaka jàdra w stopniu
zaawansowania I, IIa i IIb, u których w latach 1974-1990 przeprowadzono radioterapi´ po uprzednio wykonanej
orchidektomii. U 48% chorych obszar napromieniany obejmowa∏ wy∏àcznie uk∏ad ch∏onny podprzeponowy, a u pozosta∏ych
52% chorych dodatkowo napromieniano Êródpiersie wraz z lewym nadobojczem. Mediana obserwacji wynios∏a 12 lat.
Ryzyko wtórnych nowotworów okreÊlano w porównaniu do dopasowanej pod wzgl´dem wieku generalnej populacji m´˝czyzn,
obliczajàc stosunek liczby nowotworów obserwowanych do oczekiwanych (O/E).
W y n i k i.  Ca∏kowite prze˝ycie 5-letnie i 10-letnie wynios∏o, odpowiednio: 92% i 86%. W badanej grupie, u 12 chorych
(7%) ujawni∏o si´ 13 wtórnych nowotworów, a Êredni czas do ich wystàpienia wyniós∏ 10 lat. Wzgl´dne ryzyko (O/E)
wystàpienia wtórnych nowotworów w badanej grupie wynios∏o 3,55 (95%CI – 1,89-6,07), i by∏o znamiennie podwy˝szone.
Obserwowano znamienny statystycznie wzrost ryzyka wystàpienia raka p∏uca (O/E – 5,55; 95%CI – 2,03-12,04), i raka
odbytnicy (O/E – 11,76; 95%CI – 1,39-41,62) w porównaniu do populacji generalnej m´˝czyzn.
W n i o s e k.  Ryzyko wtórnych nowotworów jest znamiennie podwy˝szone u chorych na nasieniaka jàdra we wczesnym
stopniu zaawansowania, leczonych z zastosowaniem uzupe∏niajàcego napromieniania.
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Introduction
Seminoma accounts for about 40% of testicular germ-
cell tumours and it is usually detected in the early stage
[1]. Seminoma is a very radiosensitive neoplasm – the
standard treatment of stage I-IIa,b seminoma has been
orchidectomy followed by radiotherapy to the paraaortic
and iliac lymph nodes. The results of this approach are
excellent, with 5-year overall survival of 94% to 100%
for stage I and 85% to 100% for stage IIa and IIb [1-5].
However, the large number of long-term survivors
after succesful treatment of seminoma is at risk for late
occurring radiation effects. The most serious late effects
observed in patients treated for seminoma are second
malignancies. Several studies revealed an increased risk of
second malignancies in patients cured from testicular
tumours [2, 6-9]. Controversies remain on the increase of
the risk of second malignancies, which is attributable to
radiotherapy. Some authors did not observe a significant
increase in the risk of second malignancies in patients
with testicular tumours [10-11], whereas other authors
noted an increased risk even in non-irradiated patients [8,
13]. There are suggestions, that the increase in the risk of
second malignancies after radiotherapy for testicular
tumours may be, to a certain extent, associated with
genetic predisposition [14].
Because seminoma is highly curable, the choice of
the treatment modality should also be considered in view
of its long-term deleterious effects.
The purpose of this study was the evaluation of the
risk of second non-germ cell malignancies in a relatively
large group of patients from a single institution who
survived more than 10 years after the treatment of early
stage seminoma.
Material and methods
M a t e r i a l
A total of 201 patients with histologically confirmed stage I and
II seminoma were treated with post-orchidectomy radiotherapy
at the Cancer Center and Institute of Oncology in Gliwice,
between 1974 and 1990. A group of 170 patients was diagnosed
with early stage seminoma (I, IIa, IIb), according to the Royal
Marsden Hospital classification [15]. Six patients were excluded
from the analysis: 4 due to emigration and, thus, loss from
follow-up, 1 due to previous chemotherapy and 1 patient due to
another cancer existing previously. The final analysis is thus
based on long-term follow-up of 164 patients with stage I, IIa
and IIb seminoma.
Stage I seminoma was diagnosed in 103 patients (63%),
stage IIa and IIb – in 25 patients (15%) and 36 patients (22%),
respectively.
Mean patient age was 36 years (21 to 57 years). The
diagnostic proceures and clinical evaluation before treatment
consisted of: medical history, physical examination, chest
radiographs, intravenous pyelogram (IVP), bipedal lympho-
graphy (57% of patients) abdominal ultrasonography or CT
(45% of patients) and laboratory investigations – blood count
with evaluation of hepatic and renal function and urine analysis.
The routine treatment modality was orchidectomy
and subsequent irradiation of the regional lymph nodes
(after a median of 9 weeks), with or without prophylactic
mediastinal and left supraclavicular irradiation. Orchidectomy
was performed from a scrotal approach in 84 patients (51%)
and from an inguinal approach in 80 patients (49%).
R a d i a t i o n  t r e a t m e n t
Between 1974 and 1985 radiotherapy was delivered using 60Co
photons and afterwards with 9-23 MV X photons beams. The
PTV in all 164 patients enclosed the paraaortic and iliac lymph
nodes bilaterally (infradiaphragmatic radiotherapy-IDRT). After
a mean delay of 3 weeks prophylactic mediastinal and left
supraclavicular irradiation (supradiaphragmatic radiotherapy-
SDRT) was performed in 85 patients (52%). In a group of 103
patients with stage I seminoma, 40 patients (39%) were treated
with prophylactic SDRT. In the group of 61 patients with stage
IIa and IIb seminoma, 45 patients (74%) were treated with
prophylactic SDRT.
IDRT was preformed with 60Co photons in 96 patients
(59%) and with high energy X beams in 68 patients (41%),
using the two opposed fields (AP+PA) technique. The total
radiation dose within the target volume was specified at the
midplane and it was, generally, 40 Gy. The dose per fraction
was 1.25-1.5 Gy when one field was treated alternately each day
or 1.5-2.0 Gy per fraction when both fields were irradiated each
day (in 7 patients different dose per fraction was used).
SDRT was performed with 60Co photons in 60 patients
(71%) and with high energy X beams in 25 patients (29%).
Irradiation was delivered using a three field technique (i.e.,
mediastinum with AP+PA fields and supraclvicular fossa with
one AP field) or with two field technique (i.e., mediastinum
and supraclavicular fossa with AP+PA fields). The total
radiation dose within the target volume was, on majority, either
35 or 40 Gy, specified at mid-plane. The dose per fraction was
1.0-1.25 Gy when one field was treated alternately each day or
2.0-2.2 Gy per fraction when both fields were irradiated each
day.
E n d p o i n t s  a n d  S t a t i s t i c s
Median follow-up was 12 years (varied from 8 to 315 months),
and 96% of living patients were followed-up for a minimum of 5
years. Patients were routinely examined monthly for the first
year of observation, at 3 month intervals for the next two years
and, thereafter, at 4-6 months intervals. At the long-term
observation phase they were examined at 6-month or 12-month
intervals.
The overall survival was estimated from the date of surgery
using actuarial methods. The incidence of second malignancies
was estimated either as a crude rate or using actuarial method.
The latency to the occurrence of second malignancies was
estimated from the date of completion of radiotherapy. The
analysis of second malignancies was based on patient records
and, in case of death, also on death certificates. All second
malignancies were histologically confirmed.
Cancers of the remaining testis were excluded from the
analysis because of the probable host predisposition. Non-
melanoma skin cancers were also excluded. The risk of second
malignancies was estimated by the ratio of the observed number
of second malignancies in the study group to the expected
number of cancers (O/E) in the age-adjusted male population of
Silesia. Cancer incidence rates to calculations were taken from
the registry of the Cancer Center and Institute of Oncology in
Gliwice (unpublished), which covers the same population as
the seminoma patients. The expected number of cancers was
calculated on the basis of the person-years at risk and the
incidence rates in 1978-1989 for the age adjusted male popu-
lation [16] by the Epidemiology Department. A Poisson
distribution was assumed for the observed cases. Results were
considered statistically significant if the 95% confidence intervals
for O/E did not include 1.00. The actuarial incidence of second
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malignancies was estimated using the Kaplan-Meier method,
and the comparison in relation to the treatment volume (IDRT
vs. SDRT) was performed with the log-rank test [17].
Results
The actuarial 5-year and 10-year overall survival of the
whole group was 92% and 86%.
There were 13 subsequent cancers diagnosed in 12
patients – 6 cases of lung cancer, 2 cases of rectal cancer,
1 case of renal cancer, 1 case of tonsillar cancer, 1 case of
stomach cancer, 1 case of melanoma on the arm and 1
case of malignant lymphoma. The mean interval to the
occurrence of the second malignancies was 10 years, and
varied from 2 to 21 years. The actuarial incidence of
second malignancies was 6% at 10 years (Figure 1).
Second malignancies occurred in 7 patients treated with
IDRT alone and in 5 patients treated with IDRT+SDRT
(Table I).
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Figure 1. The actuarial incidence of second malignancies
Table I. Second malignancies in the study group
No PTV* Radiation dose** Beam energy Second Latency Location with regard 
(60Co vs XMV) malignancies (months) to PTV
1 IDRT 40 Gy / 1.25 Gy 60Co Lung cancer 23 Outside
[ – ]
2 IDRT 40 Gy / 1.25 Gy 60Co Lung cancer 48 Oudside
[ – ]
3 IDRT 40 Gy / 1.6 Gy XMV Lung cancer 122 Outside
[ – ]
4 IDRT 40 Gy / 1.25 Gy 60Co Tonsillar cancer 70 Oudside
[ – ]
5 IDRT 40 Gy / 1.25 Gy 60Co Stomach cancer 235 Inside
[ – ]
6 IDRT 40 Gy / 2.0 Gy XMV Malignant lymphoma 170 Close to
[ – ] (mesenteric)
7 IDRT 40 Gy/ 1.7 Gy XMV Melanoma mal. 116 Outside
[ – ] Rectal cancer 140 Inside
8 IDRT+SDRT 40 Gy / 1.5 Gy 60Co Lung cancer 100 Close to
[30 Gy / 1.25 Gy]
9 IDRT+SDRT 40 Gy / 1.6 Gy XMV Lung cancer 114 Close to
[14 Gy / 2.0 Gy]
10 IDRT+SDRT 40 Gy / 1.25 Gy 60Co Lung cancer 255 Close to
35 Gy / 1.25Gy
11 IDRT+SDRT 40 Gy / 1.6 Gy XMV Renal cancer 103 Close to
[35 Gy / 1.0 Gy]
12 IDRT+SDRT 40 Gy / 1.25 Gy 60Co Rectal cancer 95 Inside
[40 Gy / 2.0 Gy]
* IDRT- infradiaphragmatic radiotherapy, SDRT- supradiaphragmatic radiotherapy
** total dose / dose per fraction – IDRT; [total dose/dose per fraction] – SDRT
With regard to treatment portals, 3 cancers develo-
ped inside, 5 cases in close proximity to the PTV and in 5
cases, second cancers were located outside the PTV.
Second malignancies which were localized in-field
developed after mean latency of 13 years, those which
were localized in close proximity to the PTV developed
after a mean latency of 12 years, but malignancies which
were localized out-field occurred after a mean interval
of 6 years. In 3 patients from the group treated with IDRT
alone, lung cancer developed, however, those patients
were habitual smokers and two of those cancers occured
shortly after radiotherapy. The patient with tonsillar
cancer was a smoker too. The patient who had two
subsequent malignancies (skin melanoma on the arm
followed by rectal cancer) had a distinct history of familial
malignancies.
No significant differences were observed in the
freedom from second malignancies between patients
treated with IDRT alone or those treated with
IDRT+SDRT, actuarial 10-year freedom from second
malignancies was 94% and 93%, respectively (log-rank
1.19; p=0.23).
The relative risk of second malignancies was more
than thrice that of the age-adjusted male population of
Silesia (O/E=3.55), which was statistically significant.
Among all second malignancies, the risk of secondary
lung and rectal cancer compared to the age adjusted male
population of Silesia was significant (Table II).
Table II. The risk of second malignancies
Malignancies Observed Expected Risk 95% CI intervals
(O) (E) (O/E)
All 13 3.66 3.55 1.89-6.07
Lung cancer 6 1.08 5.55 2.03-12.04
Rectal cancer 2 0.17 11.76 1.39-41.62
The risk of second malignancies increased over the
first 10 years of observation after radiotherapy but
decreased thereafter (Table III).
Table III. The risk of second malignancies by follow-up period
Years from 1-4 5-9 ≥10
radiotherapy
Observed (O) 2 6 5
Expected (E) 0.54 1.09 2.03
Risk (O/E) 3.70 5.50 2.46
95% CI 0.45-13.29 2.03-12.02 0.80-5.74
When separately analysed, the relative risk of second
malignancies was significantly increased in the group
treated with IDRT only (O/E=5.76; 95% CI=2.48-11.34),
but not in patients treated with IDRT+SDRT (O/E=2.22;
95% CI=0.72-5.17).
Discussion
In response to the very favourable prognosis of patients
with early stage seminoma and due to the risk of late
complications after radiation treatment, a trend towards
the reduction of the target dose and treatment volume is
observed [3, 18, 19]. Furthermore, for patients with stage
I seminoma some authors advocate replacing radiation by
mono-chmotherapy [20] or even close surveillence [21]. It
is assumed that late morbidity will decrease with the
reduction of total radiation dose and PTV. In our study
relatively high total doses and extensive treatment volume
were used, as compared to the present standards of radio-
therapy of seminoma patients [3, 5, 18, 19]. However,
even if the PTV is reduced, the risk of radiation-induced
carcinogenesis still exists and therefore, it is one of the
main arguments against using radiotherapy in the mana-
gement of early stage seminoma in this group of young
patients, as it may considerably compromise survival. The
risk of second malignancies may be influenced by many
factors such as: duration of follow-up, combination of
radiation with chemotherapy, inclusion of malignancies of
the remaining testis, homogeneity of the material, sample
size and others. In this study we decided to evaluate
patients with early stage seminoma only, because of the
relatively long expected survival and homogenous
treatment (only RT post orchidectomy).
We recorded 13 cases (actuarial risk 6% at 10 years)
of second malignancies, the mean interval to their
development was 10 years and the risk (O/E) was 3.55.
Although, in many studies, the latency to second malig-
nancies increases with longer observation, our results
(highest incidence in 5-10 years post-radiotherapy) are
probably related to the duration of follow-up, but they
are consistent with results of the study of Hanks et al.
[2], in which the actuarial incidence of second malig-
nancies was very similar to our results. Table 4 compares
the results of the present study and other published
articles; it reveals that an increased risk of second
malignancies in patients with testicular cancer wasob-
served by a majority of authors, with the exception of
Coleman et al. [11]. However, in some studies, the
increase in the risk of second malignancies did not reach
the statistical significance. In the group analysed by Chao
et al. [10], the risk of second malignancies was not
statistically significant, however, that group was relatively
small. Similarly, Horwich and Bell [12], analyzing a rela-
tively large and homogeneous material and excluding
cancers of second testis, revealed only a small, statistically
insignificant increase in the relative risk.
It is not clear to what extent the incidence of second
malignancies relates to radiotherapy and to what extent to
ther factors. For instance Kleinerman et al. [8] and Travis
et al. [13] report an increased risk of second malignancies
even in non-irradiated patients. Dieckmann et al. [14]
documented multiple neoplasms in patients with testicular
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germ-cell tumours some 30% of which preceded or
occurred synchronously to testicular cancer. Such results
may reflect the contribution of genetic and enviromental
predisposition as additional to radiotherapy.
Although the techniques of irradiation used in our
study are historical (SDRT irradiation), the risk of second
malignancies was still significantly increased even in
patients treated with IDRT only. However, the technique
of “inverted Y” has been abandonned in IDRT in early
stage seminoma and maybe further reduction of the PTV
[3, 18, 19] will lead to the decrease in the risk of second
malignancies.
Among all second malignancies reported in our
patient group, the most common was lung cancer,
which remains in accordance with the observations of
Zagars et a. [22]. We have observed that secondary lung
cancer incidence was similar in patients treated with
IDRT or IDRT+SDRT, and the risk of lung cancer was
significantly increased in the whole group of patients
treated with post-orchidectomy radiotherapy. That latter
fact remains in accordance with the observations of other
authors [7, 8]. This may reflect a certain pulmonary
sensitivity to the oncogenic effects of irradiation. Tobacco
smoking certainly plays an important part in the develo-
pement of second malignancies. In the present study, all
patients who were treated with SDRT and developed
lung cancer were habitual smokers. Tobacco smoking
habits were probably even more important in patients
who were treated with IDRT alone and developed secon-
dary lung cancer. All those patients were habitual
smokers, and the interval to the development of cancer in
two of these patients was very short, thus not charac-
teristic for radiation-induced cancers [23]. The increased
risk of lung cancer in patients who were not irradiated
above the diaphragm, observed both in our study and
reported by other authors [7], (though insignificant in
the latter case) may indicate the additional influence of
patient predisposition or enviromental factors.
The rectum, which is in close proximity to the PTV,
may be another location of radiation-induced cancers,
but the risk of second rectal malignancies reported in the
literature is increased slightly and non-significantly [2,
8]. However, some authors observed a significantly higher
risk of rectal cancer, as compared to the general
population [9, 13]. Also, the time pattern for the
developement of rectal cancer reported by Travis et al. [9]
in irradiated patients was similar to our results. In our
study the risk of second rectal malignancies is increased,
however, one patient who developed rectal cancer may
have had a genetic susceptibility to malignancies.
Conclusion
The risk of second malignancies is significantly increased
in patients with early stage seminoma treated with post-
orchidectomy radiotherapy.
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